Table 1 Demographic and clinical characteristics of the study participants at baseline
Characteristic | Placebo (n = 65) | Rasagiline 1 mg (n = 65) |
|---|---|---|
Age (years) | 59.5 ± 9.2 | 58.5 ± 8.7 |
Female | 25 (38.5) | 30 (46.2) |
BMI (kg/m2) | 22.7 ± 3.1 | 23.7 ± 2.8 |
Modified HYSS score | 1.6 ± 0.5 | 1.6 ± 0.5 |
Disease duration (years) | 0.11 (0.00, 5.46) | 0.10 (0.00, 6.15) |
UPDRS score | ||
Total | 28.56 ± 1.93 | 26.14 ± 1.46 |
Part I | 1.51 ± 0.20 | 1.58 ± 0.18 |
Part II | 7.95 ± 0.58 | 7.24 ± 0.41 |
Part III | 19.10 ± 10.60 | 17.33 ± 8.67 |
CGI-S score | 3.1 ± 0.7 | 3.2 ± 0.6 |
MMSE total score | 28.5 ± 1.6 | 28.8 ± 1.6 |
Patients with concurrent disorders | 34 (52.3) | 37 (56.9) |